KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Income (2019 - 2025)

Royalty Pharma's Net Income history spans 7 years, with the latest figure at $355.9 million for Q4 2025.

  • For Q4 2025, Net Income rose 6.45% year-over-year to $355.9 million; the TTM value through Dec 2025 reached $1.3 billion, changed 0.5%, while the annual FY2025 figure was $1.3 billion, 0.5% changed from the prior year.
  • Net Income for Q4 2025 was $355.9 million at Royalty Pharma, down from $444.2 million in the prior quarter.
  • Across five years, Net Income topped out at $806.8 million in Q2 2021 and bottomed at -$610.0 million in Q4 2022.
  • The 5-year median for Net Income is $278.1 million (2021), against an average of $291.3 million.
  • The largest annual shift saw Net Income crashed 1236.61% in 2022 before it surged 10243.53% in 2025.
  • A 5-year view of Net Income shows it stood at $53.7 million in 2021, then plummeted by 1236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then crashed by 53.41% to $334.4 million in 2024, then rose by 6.45% to $355.9 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Net Income are $355.9 million (Q4 2025), $444.2 million (Q3 2025), and $90.6 million (Q2 2025).